
    
      In this study, the investigator would like to better understand the efficacy and safety of
      the addition of polatuzumab vedotin to therapy with rituximab, cyclophosphamide, doxorubicin,
      vincristine and prednisone (R-CHOP) and dose attenuated R-CHOP in patients who are aged 75
      years and older.
    
  